Halozyme Therapeutics, Inc.
HALO
$63.65
-$1.48-2.27%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 51.60% | 22.12% | 40.79% | 35.22% | 29.55% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 51.60% | 22.12% | 40.79% | 35.22% | 29.55% |
| Cost of Revenue | 77.08% | 6.79% | 17.05% | 63.01% | -15.13% |
| Gross Profit | 44.83% | 26.81% | 45.69% | 29.86% | 50.58% |
| SG&A Expenses | 49.89% | 11.75% | 16.53% | 20.57% | 12.34% |
| Depreciation & Amortization | 31.61% | 0.00% | 0.00% | -0.01% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 61.11% | 7.45% | 8.03% | 22.91% | -5.04% |
| Operating Income | 44.95% | 33.53% | 72.68% | 48.14% | 73.70% |
| Income Before Tax | -156.59% | 32.58% | 74.06% | 49.78% | 76.14% |
| Income Tax Expenses | -1.12% | 55.43% | 62.37% | 33.99% | 160.99% |
| Earnings from Continuing Operations | -203.34% | 27.89% | 77.12% | 53.72% | 60.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -203.34% | 27.89% | 77.12% | 53.72% | 60.46% |
| EBIT | 44.95% | 33.53% | 72.68% | 48.14% | 73.70% |
| EBITDA | 43.47% | 30.02% | 62.75% | 40.35% | 61.52% |
| EPS Basic | -211.02% | 38.40% | 85.56% | 58.36% | 63.83% |
| Normalized Basic EPS | 53.71% | 43.48% | 82.35% | 56.34% | 81.90% |
| EPS Diluted | -213.33% | 36.19% | 84.72% | 55.00% | 62.31% |
| Normalized Diluted EPS | 56.83% | 41.04% | 81.14% | 54.43% | 81.01% |
| Average Basic Shares Outstanding | -6.91% | -7.59% | -4.54% | -2.94% | -2.05% |
| Average Diluted Shares Outstanding | -8.77% | -6.00% | -3.92% | -1.74% | -1.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |